Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 1Neoplasms 1Cancer Pain 1Breakthrough Pain 1

Interventions

Fentanyl 9Acetaminophen 5Zoledronic Acid 4Oxycodone 4Ketamine 4Bupivacaine 4Sufentanil 3Hydromorphone 3Diclofenac 3Ropivacaine 2Pregabalin 2Morphine 2Ketorolac 2Ibuprofen 2Ibandronic Acid 2Esketamine 2Epinephrine 2naloxegol 1chloroprocaine 1acetaminophen, aspirin, caffeine drug combination 1Varenicline 1Uterine Artery Embolization 1Ultracet 1Therapeutics 1Propofol 1Pamidronate 1Oxygen 1Nitrous Oxide 1Naproxen 1Midazolam 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Pain × Ultracet × Clear all
NCT00576173 2010-04-28

An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients

Johnson & Johnson Taiwan Ltd

Phase 4 Completed
60 enrolled

Cancer Pain, Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡